OOIR: Observatory of International Research

Papers

(The H4-Index of EMBO Molecular Medicine is 41. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC	335
Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders	223
Circulating proteomic panels for risk stratification of intracranial aneurysm and its rupture	134
Whole‐brain microscopy reveals distinct temporal and spatial efficacy of anti‐Aβ therapies	132
THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer	124
The state of the art of bispecific antibodies for treating human malignancies	118
A preclinical model of peripheral T‐cell lymphoma GATA3 reveals DNA damage response pathway vulnerability	112
Targeting the Leukemic stem cell protein machinery by inhibition of mitochondrial pyrimidine synthesis	106
Targetable Brg1‐CXCL14 axis contributes to alcoholic liver injury by driving neutrophil trafficking	91
Targeting conformational changes in C‐reactive protein to inhibit pro‐inflammatory actions	88
Elongator and the role of its subcomplexes in human diseases	82
HIF2α activation and mitochondrial deficit due to iron chelation cause retinal atrophy	70
Depressive patient‐derived GABA interneurons reveal abnormal neural activity associated with HTR2C	68
TFEB and TFE3 drive kidney cystogenesis and tumorigenesis	65
Flower lose, a cell fitness marker, predicts COVID‐19 prognosis	64
IQCN disruption causes fertilization failure and male infertility due to manchette assembly defect	63
When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease	63
Activation of the integrated stress response is a vulnerability for multidrug‐resistant FBXW7 ‐deficient cells	62
Glomerular endothelial cell senescence drives age‐related kidney disease through PAI‐1	56
ASO targeting RBM3 temperature‐controlled poison exon splicing prevents neurodegeneration in vivo	55
Metformin rescues migratory deficits of cells derived from patients with periventricular heterotopia	55
Identification of treatment‐induced vulnerabilities in pancreatic cancer patients using functional model systems	54
Molecular and cognitive signatures of ageing partially restored through synthetic delivery of IL2 to the brain	54
Eosinophil‐derived IL ‐4 is necessary to establish the inflammatory structure in innate inflammation	53
Diagnostic biomarkers for active tuberculosis: progress and challenges	53

Systemic inflammation after stroke: implications for post‐stroke comorbidities	50
Tau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers	49
Single‐cell profiling of muscle‐infiltrating T cells in idiopathic inflammatory myopathies	49
Autosomal recessive pathogenic MSTO1 variants in hereditary optic atrophy	49
Nerve regeneration by interferon intervention in aging brain	48
Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer	48
Pharmacological or genetic inhibition of iNOS prevents cachexia‐mediated muscle wasting and its associated metabolism defects	48
Shear stress control of vascular leaks and atheromas through Tie2 activation by VE‐PTP sequestration	47
Spleen tyrosine kinase mediates innate and adaptive immune crosstalk in SARS‐CoV‐2 mRNA vaccination	46
Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model	44
Functions of double‐negative B cells in autoimmune diseases, infections, and cancers	44
Advances in high‐throughput mass spectrometry in drug discovery	43
ALX1 ‐related frontonasal dysplasia results from defective neural crest cell development and migration	43
Looking at a baby's heart through the lens of the mother's blood	43
Mining the bacterial genome to discover new antimicrobial molecules	42
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer	41